Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hapvida Participações e Investimentos S.A. (HAPV3.SA)
Fortaleza, CE, BR
Hapvida Participações e Investimentos S.A., operating alongside its affiliated companies, is a key player in the Brazilian healthcare sector. The organization provides a variety of health and dental insurance plans. Its service offerings extend to direct medical and paramedical care, complemented by a suite of diagnostic services such as laboratory analysis, imaging, and ultrasound. Additionally, Hapvida supports educational initiatives by organizing courses, lectures, seminars, and similar events. The company is also involved in the administration, consultancy, deployment, and sale of individual, family, and collective healthcare systems and plans. It manages the reimbursement of medical, dental, hospital, and general healthcare expenses for its members, while simultaneously offering direct medical and hospital services. Hapvida maintains an extensive operational infrastructure, comprising 85 hospitals, 77 emergency units, 318 clinics, and 269 diagnostic centers. The company was founded in 1979 and is headquartered in Fortaleza, Brazil.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.92% | +6.17% | -2.52% | +22.50% | -32.56% | -12.50% | -68.07% | -73.04% | -94.18% | -84.75% | -84.75% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 0 | -1 |
| Hold | 12 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Insurance - Specialty: +11.0%+9.2% Q1'26: -82.2% (vs Q1'25)
-
EPS growth Insurance - Specialty: +18.3%+78.0% ★ Q1'26: -156.8% (vs Q1'25)
-
FCF margin FCF growth · Insurance - Specialty: +39.7%-7.5% Q1'26: +35.1% (vs Q1'25)
-
EBIT margin Insurance - Specialty: +18.3%+4.5% Q1'26: +39.9% (vs Q1'25)
-
ROIC Insurance - Specialty: +10.3%+2.5% Q1'26: +2.4% (vs Q1'25)
-
Share dilution Insurance - Specialty: +0.5%-1.5% ★ Q1'26: -6.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Insurance - Specialty: 0.25×6.78× Q1'26: 5.78× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 2 EPS Ana. |
Dec 2027 13 Rev. Ana. 6 EPS Ana. |
Dec 2028 10 Rev. Ana. 3 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 5 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.58B
est: 4.59B (-0.2%)
|
5.63B
est: 5.53B (+1.8%)
|
8.55B
est: 8.52B (+0.4%)
|
9.88B
est: 9.91B (-0.3%)
|
23.75B
est: 23.98B (-1.0%)
|
27.95B
est: 27.33B (+2.2%)
|
28.91B
est: 28.94B (-0.1%)
|
31.58B
est: 30.90B (+2.2%)
|
32.39B
31.90B – 34.59B
+4.8% YoY
|
34.13B
33.14B – 38.63B
+5.4% YoY
|
36.06B
36.06B – 36.06B
+5.7% YoY
|
37.86B
37.29B – 40.43B
+5.0% YoY
|
41.45B
40.83B – 44.27B
+9.5% YoY
|
| EBITDA |
1.13B
est: 675.05M (+66.8%)
|
1.45B
est: 814.41M (+78.4%)
|
2.03B
est: 1.25B (+62.3%)
|
1.62B
est: 1.46B (+11.2%)
|
2.35B
est: 3.53B (-33.5%)
|
3.37B
est: 3.12B (+8.2%)
|
3.31B
est: 3.30B (+0.3%)
|
2.28B
est: 3.52B (-35.3%)
|
3.69B
3.64B – 3.94B
+4.8% YoY
|
3.89B
3.78B – 4.40B
+5.4% YoY
|
4.11B
4.11B – 4.11B
+5.7% YoY
|
4.32B
4.25B – 4.61B
+5.0% YoY
|
4.73B
4.66B – 5.05B
+9.5% YoY
|
| EBIT |
1.08B
est: 318.96M (+239.7%)
|
1.25B
est: 384.81M (+225.6%)
|
1.28B
est: 592.45M (+116.4%)
|
727.03M
est: 689.07M (+5.5%)
|
159.07M
est: 1.67B (-90.5%)
|
1.75B
est: 1.33B (+31.8%)
|
1.59B
est: 1.40B (+13.5%)
|
1.41B
est: 1.50B (-6.0%)
|
1.57B
1.55B – 1.68B
+4.8% YoY
|
1.65B
1.61B – 1.87B
+5.4% YoY
|
1.75B
1.75B – 1.75B
+5.7% YoY
|
1.84B
1.81B – 1.96B
+5.0% YoY
|
2.01B
1.98B – 2.15B
+9.5% YoY
|
| Net Income |
787.47M
est: 1.74B (-54.8%)
|
849.83M
est: 1.86B (-54.2%)
|
783.46M
est: 2.05B (-61.8%)
|
497.80M
est: 1.21B (-58.9%)
|
-777.23M
est: -155.48M (-399.9%)
|
-615.15M
est: -37.77M (-1,528.5%)
|
-649.30M
est: 1.16B (-156.1%)
|
-141.75M
est: 1.01B (-114.1%)
|
426.94M
404.68M – 449.21M
-57.7% YoY
|
724.14M
470.82M – 1.46B
+69.6% YoY
|
973.51M
559.33M – 1.80B
+34.4% YoY
|
1.04B
1.02B – 1.13B
+7.0% YoY
|
1.81B
1.77B – 1.97B
+73.5% YoY
|
| SGA |
950.59M
est: 256.72M (+270.3%)
|
521.55M
est: 309.72M (+68.4%)
|
694.40M
est: 476.84M (+45.6%)
|
824.17M
est: 554.60M (+48.6%)
|
2.00B
est: 1.34B (+49.3%)
|
550.26M
est: 1.30B (-57.7%)
|
324.95M
est: 1.38B (-76.4%)
|
1.24B
est: 1.47B (-15.5%)
|
1.54B
1.52B – 1.65B
+4.8% YoY
|
1.62B
1.58B – 1.84B
+5.4% YoY
|
1.72B
1.72B – 1.72B
+5.7% YoY
|
1.80B
1.78B – 1.92B
+5.0% YoY
|
1.97B
1.94B – 2.11B
+9.5% YoY
|
| EPS |
0.23
est: 3.42 (-93.3%)
|
0.22
est: 3.65 (-94.0%)
|
0.21
est: 4.03 (-94.8%)
|
0.13
est: 2.38 (-94.5%)
|
-0.11
est: -0.30 (+63.6%)
|
-0.08
est: -0.07 (-9.9%)
|
-1.27
est: 2.23 (-157.0%)
|
-0.28
est: 1.91 (-114.7%)
|
0.82
0.81 – 0.90
-56.9% YoY
|
1.49
0.94 – 2.91
+81.0% YoY
|
2.12
1.11 – 3.59
+42.3% YoY
|
2.08
2.03 – 2.26
-2.0% YoY
|
3.60
3.53 – 3.92
+73.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cideria Barbosa da Costa | Chief Operating Officer | — | female |
| Eliana Vieira | Vice President of HR & Diversity and Member of Board of Executive Officers | — | — |
| Felipe Araújo | Vice President of HR, Diversity and Sustainability & Member of Board of Executive Officers | — | — |
| Fernando Miguel Augusto | Accounting Director | — | — |
| Gustavo Henrique Zacharias Ribeiro | Statutory Chief of Institutional Relations Officer & Member of Board of Executive Officers | — | male |
| Igor Macedo Faco | Statutory Chief Legal Officer & Member of Board of Executive Officers | — | male |
| Jaqueline Sena | Vice President of Dental & Member of Board of Executive Officers | — | — |
| Jorge Fontoura Pinheiro Koren de Lima | Statutory Chief Executive Officer, Member of Board of Executive Officers & Director | — | male |
| Luccas Adib | Statutory Chief Financial Officer & Investor Relations Officer and Vice President of Technology and Innovation | — | male |
| Milaine Lima | VP of Medical, Assistance Regulation & Auditing and Member of Board of Executive Officers | — | — |
| Nico Camargo | VP of Client & Member of Board of Executive Officers | — | — |
| Rafael Andrade | Vice-President Commercial & Member of Board of Executive Officers | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HAPV3.SA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
